-

Bruker Announces New Fraport AG Framework Contract for ETD Systems

Largest German airport FRA to modernize passenger security with up to 220 Bruker high-performance explosives trace detector (ETD) systems DE-tector™ flex

FRANKFURT, Germany--(BUSINESS WIRE)--Fraport AG has announced the procurement decision in favor of Bruker for the provision of up to 220 DE-tector™ flex explosives and narcotics trace detectors to support their airport security measures. The installations are planned over a multi-year period from 2023 to 2027 to modernize the screening of passengers at Germany’s busiest airport FRA. The next-generation, high-performance Bruker DE-tector flex systems are intended to replace earlier-generation Bruker ETD systems at Frankfurt airport.

The Bruker DE-tector flex is a next-generation transportable explosives and narcotics trace detector that meets the requirements of two important security applications in airports, namely drugs (D) and explosives (E) detection. By wiping surfaces with multi-use, disposable swabs, and inserting them into the DE-tector flex, traces of most explosives and many illegal drug substances can be identified automatically within seconds. The new DE-tector flex system is certified by ECAC (European Civil Aviation Conference) as well as by national authorities, and it utilizes a non-radioactive ionization source.

“These next-generation systems will replace earlier explosive trace detectors at Frankfurt Airport and modernize the screening of passengers. The certification of the DE-tector flex system provides us with confidence that we are utilizing the most innovative and safe technology available. We look forward to continuing our partnership with Bruker to ensure the safety and security of our passengers and of the aviation industry," commented Sascha König, Head of Resource Management and Infrastructure Terminals, Fraport AG.

Dr. Andreas Kamlowski, President of the Bruker Optics Division, stated: “We are delighted that Fraport AG has again selected Bruker to provide innovative and reliable solutions to support the safety and security of the public and of the aviation industry. Bruker is fully committed to continue the long-term supplier partnership that started with the first installation of Bruker ETD detectors at FRA in 2015.”

About Bruker Corporation
Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.

Contacts

Investor:
Justin Ward
Sr. Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Media:
Michael Mueller
Marketing Manager
Bruker Optics GmbH & Co. KG
T: +49 7243 504 2652

Bruker Corporation

NASDAQ:BRKR

Release Versions
$Cashtags
Hashtags

Contacts

Investor:
Justin Ward
Sr. Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Media:
Michael Mueller
Marketing Manager
Bruker Optics GmbH & Co. KG
T: +49 7243 504 2652

Social Media Profiles
More News From Bruker Corporation

Bruker Announces Date and Time of First Quarter 2026 Earnings Release and Webcast

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced it will report first quarter 2026 financial results before market opening on Wednesday, May 6, 2026. The Company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q1 2026 Earnings Webcast” hyperlink in the “Events & Presentations” section. A slide presenta...

Bruker Spatial Biology Showcases High Fidelity Spatial Data and Integrated Multi-platform Workflows for Unprecedented Multiomic Insights at AACR 2026

SAN DIEGO--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced new updates from Bruker Spatial Biology to be showcased at the 2026 American Association for Cancer Research (AACR) Annual Meeting. At AACR, Bruker Spatial Biology will highlight how its high-fidelity spatial platforms—designed to work together—deliver deeper insights into oncology biology and accelerate translational research. At AACR 2026, Bruker Spatial Biology will launch new cross‑platform workflows linking GeoMx...

Bruker Expands Industry-Leading MALDI Biotyper® and IR Biotyper® Workflows for Microbial Identification and Outbreak Management

MUNICH--(BUSINESS WIRE)--At ESCMID Global 2026, Bruker announces important portfolio enhancements across microbial identification, outbreak analysis, and reflex next‑generation sequencing (NGS) typing. These latest developments underscore Bruker’s continued commitment to advancing integrated, high‑performance solutions that support laboratories in addressing evolving infectious disease challenges. MALDI Biotyper® Workflow and Identification Enhancements To further streamline routine MALDI‑TOF w...
Back to Newsroom